Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $29.29 Consensus Target Price from Analysts

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has earned an average recommendation of “Moderate Buy” from the eleven research firms that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $29.2857.

A number of equities research analysts recently issued reports on the company. Wall Street Zen cut Zevra Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, June 6th. Citizens Jmp increased their target price on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “market outperform” rating in a research report on Tuesday, June 9th. Guggenheim lifted their target price on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Cantor Fitzgerald boosted their price target on shares of Zevra Therapeutics from $24.00 to $34.00 and gave the company an “overweight” rating in a research report on Monday, June 8th. Finally, Canaccord Genuity Group upped their price target on shares of Zevra Therapeutics from $24.00 to $29.00 and gave the company a “buy” rating in a research note on Tuesday, June 9th.

Institutional Investors Weigh In On Zevra Therapeutics

Institutional investors have recently made changes to their positions in the stock. Gunpowder Capital Management LLC dba Oliver Wealth Management purchased a new position in shares of Zevra Therapeutics in the fourth quarter valued at $53,000. Russell Investments Group Ltd. lifted its holdings in Zevra Therapeutics by 235.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock worth $61,000 after purchasing an additional 4,475 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Zevra Therapeutics by 617.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock worth $88,000 after purchasing an additional 8,552 shares during the period. Creative Planning bought a new position in Zevra Therapeutics in the 2nd quarter worth about $92,000. Finally, Qube Research & Technologies Ltd bought a new position in Zevra Therapeutics in the 2nd quarter worth about $99,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Stock Performance

NASDAQ:ZVRA traded up $0.48 during trading hours on Tuesday, reaching $14.45. The stock had a trading volume of 983,420 shares, compared to its average volume of 1,321,427. The stock has a 50 day simple moving average of $11.76 and a 200 day simple moving average of $10.06. Zevra Therapeutics has a 12-month low of $7.16 and a 12-month high of $14.58. The stock has a market cap of $854.28 million, a P/E ratio of 7.27 and a beta of 0.85.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.12. The firm had revenue of $36.22 million for the quarter, compared to analysts’ expectations of $31.96 million. Zevra Therapeutics had a return on equity of 51.49% and a net margin of 101.58%. On average, equities analysts expect that Zevra Therapeutics will post 0.56 earnings per share for the current fiscal year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.